Andrea J MacNeill1,2, Rosalba Miceli3, Dirk C Strauss4, Sylvie Bonvalot5, Peter Hohenberger6, Frits Van Coevorden7, Piotr Rutkowski8, Dario Callegaro2, Andrew J Hayes4, Charles Honoré9, Mark Fairweather10, Amanda Cannell11, Jens Jakob6, Rick L Haas12, Milena Szacht8, Marco Fiore2, Paolo G Casali13, Raphael E Pollock14, Chandrajit P Raut10, Alessandro Gronchi2, Carol J Swallow1. 1. Department of Surgical Oncology, Mount Sinai Hospital and Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada. 2. Department of Surgery, IRCCS Foundation National Cancer Institute, Milan, Italy. 3. Department of Biostatistics, IRCCS Foundation National Cancer Institute, Milan, Italy. 4. Department of Surgery, Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom. 5. Department of Surgery, Curie Institute, Paris, France. 6. University Medical Center Mannheim, University of Heidelberg, Mannheim, Germany. 7. Department of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands. 8. Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland. 9. Department of Surgery, Gustave Roussy Institute, Villejuif, France. 10. Division of Surgical Oncology, Department of Surgery, Brigham and Women's Hospital and Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. 11. Ontario Institute for Cancer Research, MaRS Centre, Toronto, Ontario, Canada. 12. Department of Radiation Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands. 13. Department of Cancer Medicine, IRCCS Foundation National Cancer Institute, Milan, Italy. 14. Division of Surgical Oncology, Department of Surgery, Ohio State University Medical Center, Columbus, Ohio.
Abstract
BACKGROUND: Despite a radical surgical approach to primary retroperitoneal sarcoma (RPS), many patients experience locoregional and/or distant recurrence. The objective of this study was to analyze post-relapse outcomes for patients with RPS who had initially undergone surgical resection of their primary tumor at a specialist center. METHODS: All consecutive patients who underwent macroscopically complete resection for primary RPS at 8 high volume centers from January 2002 to December 2011 were identified, and those who developed local recurrence (LR) only, distant metastasis (DM) only, or synchronous local recurrence and distant metastasis (LR+DM) during the follow-up period were included. Overall survival (OS) was calculated for all groups, as was the crude cumulative incidence of a second recurrence after the first LR. Multivariate analyses for OS were performed. RESULTS: In an initial series of 1007 patients with primary RPS, 408 patients developed recurrent disease during the follow-up period. The median follow-up from the time of recurrence was 41 months. The median OS was 33 months after LR (n = 219), 25 months after DM (n = 146), and 12 months after LR+DM (n = 43), and the 5-year OS rates were 29%, 20%, and 14%, respectively. Predictors of OS after LR were the time interval to LR and resection of LR, while histologic grade approached significance. For DM, significant predictors of OS were the time interval to DM and histologic subtype. The subgroup of patients who underwent resection of recurrent disease had a longer median OS than patients who did not undergo resection. CONCLUSIONS: Relapse of RPS portends high disease-specific mortality. Patients with locally recurrent or metastatic disease should be considered for resection. Cancer 2017;123:1971-1978.
BACKGROUND: Despite a radical surgical approach to primary retroperitoneal sarcoma (RPS), many patients experience locoregional and/or distant recurrence. The objective of this study was to analyze post-relapse outcomes for patients with RPS who had initially undergone surgical resection of their primary tumor at a specialist center. METHODS: All consecutive patients who underwent macroscopically complete resection for primary RPS at 8 high volume centers from January 2002 to December 2011 were identified, and those who developed local recurrence (LR) only, distant metastasis (DM) only, or synchronous local recurrence and distant metastasis (LR+DM) during the follow-up period were included. Overall survival (OS) was calculated for all groups, as was the crude cumulative incidence of a second recurrence after the first LR. Multivariate analyses for OS were performed. RESULTS: In an initial series of 1007 patients with primary RPS, 408 patients developed recurrent disease during the follow-up period. The median follow-up from the time of recurrence was 41 months. The median OS was 33 months after LR (n = 219), 25 months after DM (n = 146), and 12 months after LR+DM (n = 43), and the 5-year OS rates were 29%, 20%, and 14%, respectively. Predictors of OS after LR were the time interval to LR and resection of LR, while histologic grade approached significance. For DM, significant predictors of OS were the time interval to DM and histologic subtype. The subgroup of patients who underwent resection of recurrent disease had a longer median OS than patients who did not undergo resection. CONCLUSIONS: Relapse of RPS portends high disease-specific mortality. Patients with locally recurrent or metastatic disease should be considered for resection. Cancer 2017;123:1971-1978.
Authors: Naruhiko Ikoma; Keila E Torres; Heather Y Lin; Vinod Ravi; Christina L Roland; Gary N Mann; Kelly K Hunt; Janice N Cormier; Barry W Feig Journal: J Surg Oncol Date: 2017-05-29 Impact factor: 3.454
Authors: Konstantinos Chouliaras; Rebecca Senehi; Cecilia G Ethun; George Poultsides; Thuy Tran; Valerie Grignol; Thomas Clark Gamblin; Kevin K Roggin; Jennifer Tseng; Ryan C Fields; Sharon M Weber; Gregory B Russell; Edward A Levine; Kenneth Cardona; Konstantinos Votanopoulos Journal: J Surg Oncol Date: 2019-06-27 Impact factor: 3.454
Authors: Emily Z Keung; Nikita Rajkot; Keila E Torres; Neeta Somaiah; Kelly K Hunt; Barry W Feig; Christopher P Scally; Naruhiko Ikoma; Christina L Roland Journal: Ann Surg Oncol Date: 2020-05-14 Impact factor: 5.344
Authors: Michael J Nathenson; Constance M Barysauskas; Robert A Nathenson; William F Regine; Nader Hanna; Edward Sausville Journal: World J Surg Oncol Date: 2018-10-11 Impact factor: 2.754
Authors: María Reynel; Yván Villegas; Paul G Werthmann; Helmut Kiene; Gunver S Kienle Journal: Integr Cancer Ther Date: 2021 Jan-Dec Impact factor: 3.279